China Biologic Products Holdings, Inc. (CBPO): Price and Financial Metrics

China Biologic Products Holdings, Inc. (CBPO)

Today's Latest Price: $106.41 USD

0.06 (0.06%)

Updated Aug 3 1:56pm

Add CBPO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 115 in China

See all "A" rated Strong Buy stocks

CBPO Stock Summary

  • For CBPO, its debt to operating expenses ratio is greater than that reported by only 0.32% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.15 for China Biologic Products Holdings Inc; that's greater than it is for just 9.87% of US stocks.
  • In terms of volatility of its share price, CBPO is more volatile than merely 0.34% of stocks we're observing.
  • Stocks that are quantitatively similar to CBPO, based on their financial statements, market capitalization, and price volatility, are ROLL, TTGT, TC, MC, and PIH.
  • Visit CBPO's SEC page to see the company's official filings. To visit the company's web site, go to
CBPO Daily Price Range
CBPO 52-Week Price Range

CBPO Stock Price Chart Technical Analysis Charts

CBPO Price/Volume Stats

Current price $106.41 52-week high $119.44
Prev. close $106.35 52-week low $92.22
Day low $105.30 Volume 44,011
Day high $107.14 Avg. volume 113,982
50-day MA $107.33 Dividend yield N/A
200-day MA $111.75 Market Cap 4.19B

China Biologic Products Holdings, Inc. (CBPO) Company Bio

China Biologic Products engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in China. The company is based in Beijing, the China.

CBPO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$106.41$191.91 80%

Below please find a table outlining a discounted cash flow forecast for CBPO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that China Biologic Products Holdings Inc ranked in the 60th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of China Biologic Products Holdings Inc, consider:

  • Interest coverage, a measure of earnings relative to interest payments, is 312.17 -- which is good for besting 97.39% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than just 0% of the free cash flow producing stocks we're observing.
  • CBPO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 61.19% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of China Biologic Products Holdings Inc? See DRRX, PBH, UTHR, NHC, and RSCF.

CBPO Latest News Stream

Event/Time News Detail
Loading, please wait...

CBPO Latest Social Stream

Loading social stream, please wait...

View Full CBPO Social Stream

Latest CBPO News From Around the Web

Below are the latest news stories about China Biologic Products Holdings Inc that investors may wish to consider to help them evaluate CBPO as an investment opportunity.

5 Profitable Companies With a Margin of Safety

Comcast makes the list Continue reading...

Yahoo | July 13, 2020

5 Health Care Stocks Boosting Earnings

Biogen tops the list Continue reading...

Yahoo | June 30, 2020

China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan") to China Biologic, which attempts to terminate the cooperation between China Biologic and Xinjiang Deyuan, and urges Xinjiang Deyuan to cure its breaches and continue to perform its obligations under its cooperation agreement with China Biologic. In addition, the Company announced that, through the lawsuits it previously filed against Xinjiang Deyuan, the Company is seeking monetary claims totaling over RMB460 million and has obtained judicial freezing of certain s...

Yahoo | June 29, 2020

Hedge Funds Are Selling China Biologic Products Holdings Inc (CBPO)

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | June 26, 2020

China Biologic Products Inc (CBPO) Q1 2020 Earnings Call Transcript

An earnings release is available on the Company's website. Today, you will hear from China Biologic's Chairman and CEO, Mr. Joseph Chow, who will start off the call with a review of the Company's basic operating results and report recent developments for the Company. China Biologic's CFO, Mr. Ming Yang, will be available during the Q&A session following the prepared remarks.

Yahoo | May 21, 2020

Read More 'CBPO' Stories Here

CBPO Price Returns

1-mo N/A
3-mo -0.46%
6-mo -8.55%
1-year 11.05%
3-year 9.66%
5-year -13.79%
YTD -8.57%
2019 53.31%
2018 -3.63%
2017 -26.74%
2016 -24.53%
2015 111.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.041 seconds.